CLEARSIDE BIOMEDICAL INC (CLSD)

Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye

ALPHARETTA, Ga., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of...

Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States

- Commercial, Clinical and Regulatory Expertise Establish Clearside as the Leader in Suprachoroidal Delivery - - Multiple Events at Asia-Pacific...

Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema

- Partnership Creates New Opportunities to Address Unmet Needs Related to Posterior Segment Eye Diseases in China - - Agreement Provides Additional...

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

ALPHARETTA, Ga., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of...

Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors

ALPHARETTA, Ga., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of...

Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024

ALPHARETTA, Ga., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of...

Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting

- CLS-AX Phase 3 Ready Based on Positive Phase 2b Topline Data in Wet AMD - - Differentiated Profile for CLS-AX Targeting Flexible Dosing Similar to a...

Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

- Maintained Stable Visual Acuity and Anatomical Control Over 9 Months - - Positive Safety Profile with No Ocular or Treatment-Related Serious Adverse...

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

- CLS-AX is a Highly Potent Tyrosine Kinase Inhibitor Delivered Suprachoroidally Using Clearside’s Proprietary SCS Microinjector® - - Topline Data...

CLSD Stock Earnings: Clearside Biomedical Beats EPS, Misses Revenue for Q2 2024

CLSD stock results show that Clearside Biomedical beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.

CLSD Stock Earnings: Clearside Biomedical Beats EPS, Misses Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Clearside Biomedical (NASDAQ:CLSD) just reported results for the second quarter...

Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update

- Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected in Late Q3 2024 - - ODYSSEY Safety Review Committee Recommends Trial...

Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

ALPHARETTA, Ga., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of...

Clearside Biomedical to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024

ALPHARETTA, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of...

Clearside Biomedical Opens Registration for Suprachoroidal Delivery KOL Webinar to Be Held on Wednesday, July 24, 2024 at 8:00 am ET

ALPHARETTA, Ga., July 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of...

Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board

ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of...

Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery

- Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET - - Retina Specialists to Provide Insights and Real-World Experience with Suprachoroidal...

Clearside Biomedical’s Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting

- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - Robust Safety Profile and Encouraging Efficacy Data...

Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA®

- Expert Panel of Ophthalmologists Developed Professional Guidelines in Using the Innovative Technique for Retinal Therapeutic Delivery - - Current...

CLSD Stock Earnings: Clearside Biomedical Misses EPS, Misses Revenue for Q1 2024

CLSD stock results show that Clearside Biomedical missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

CLSD Stock Earnings: Clearside Biomedical Misses EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Clearside Biomedical (NASDAQ:CLSD) just reported results for the first quarter ...

Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference

ALPHARETTA, Ga., May 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of...

Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024

ALPHARETTA, Ga., April 30, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery...

Friday 4/19 Insider Buying Report: CLSD, ULS

Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors

Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors...

7 Top Stocks Under $7

Stocks under $7 have greater potential for substantial gains because they start off with lower valuations. Here are some of the best now.

Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

ALPHARETTA, Ga., April 02, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery...

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Industry Veteran with Extensive Experience in Retinal Disease Research and Strong Track Record in Advancing Programs Through Clinical Development...